螺环β-内酯蛋白酶体抑制剂的结构分析
Structural analysis of spiro beta-lactone proteasome inhibitors.
作者信息
Groll Michael, Balskus Emily P, Jacobsen Eric N
机构信息
Center for Integrated Protein Science at the Department Chemie, Lehrstuhl für Biochemie, Technische Universität München, Lichtenbergstrasse 4, D-85747 Garching, Germany.
出版信息
J Am Chem Soc. 2008 Nov 12;130(45):14981-3. doi: 10.1021/ja806059t. Epub 2008 Oct 17.
Abstract
Spiro beta-lactone-based proteasome inhibitors were discovered in the context of an asymmetric catalytic total synthesis of the natural product (+)-lactacystin (1). Lactone 4 was found to be a potent inhibitor of the 26S proteasome, while its C-6 epimer (5) displayed weak activity. Crystallographic studies of the two analogues covalently bound to the 20S proteasome permitted characterization of the important stabilizing interactions between each inhibitor and the proteasome's key catalytic N-terminal threonine residue. This structural data support the hypothesis that the discrepancy in potency between 4 and 5 may be due to differences in the hydrolytic stabilities of the resulting acyl enzyme complexes.
摘要
基于螺环β-内酯的蛋白酶体抑制剂是在天然产物(+)-乳胞素(1)的不对称催化全合成过程中发现的。发现内酯4是26S蛋白酶体的有效抑制剂，而其C-6差向异构体(5)活性较弱。对与20S蛋白酶体共价结合的两种类似物的晶体学研究，使得能够表征每种抑制剂与蛋白酶体关键催化N端苏氨酸残基之间重要的稳定相互作用。这一结构数据支持了这样的假设，即4和5之间效力的差异可能是由于所得酰基酶复合物水解稳定性的差异。
相似文献
1
Structural analysis of spiro beta-lactone proteasome inhibitors.螺环β-内酯蛋白酶体抑制剂的结构分析
J Am Chem Soc. 2008 Nov 12;130(45):14981-3. doi: 10.1021/ja806059t. Epub 2008 Oct 17.
2
Synthesis and bioactivity of fused- and spiro-β-lactone-lactam systems.稠合和螺环-β-内酯-内酰胺体系的合成与生物活性
Org Biomol Chem. 2017 Jun 27;15(25):5373-5379. doi: 10.1039/c7ob01148b.
3
Alpha,beta-unsaturated beta-silyl imide substrates for catalytic, enantioselective conjugate additions: a total synthesis of (+)-lactacystin and the discovery of a new proteasome inhibitor.用于催化对映选择性共轭加成的α，β-不饱和β-硅基酰亚胺底物：（+）-乳胞素的全合成及一种新型蛋白酶体抑制剂的发现
J Am Chem Soc. 2006 May 31;128(21):6810-2. doi: 10.1021/ja061970a.
4
Proteasome structure, function, and lessons learned from beta-lactone inhibitors.蛋白酶体结构、功能及β-内酰胺抑制剂的启示
Curr Top Med Chem. 2011 Dec;11(23):2850-78. doi: 10.2174/156802611798281320.
5
Glutathiolation of the proteasome is enhanced by proteolytic inhibitors.蛋白酶体的谷胱甘肽化作用会被蛋白酶抑制剂增强。
Arch Biochem Biophys. 2001 May 15;389(2):254-63. doi: 10.1006/abbi.2001.2332.
6
A Minimal β-Lactone Fragment for Selective β5c or β5i Proteasome Inhibitors.用于选择性β5c 或β5i 蛋白酶体抑制剂的最小 β-内酯片段。
Angew Chem Int Ed Engl. 2015 Jun 26;54(27):7810-4. doi: 10.1002/anie.201502931. Epub 2015 May 14.
7
(-)-Homosalinosporamide A and Its Mode of Proteasome Inhibition: An X-ray Crystallographic Study.(-)-Homosalinosporamide A 及其蛋白酶体抑制模式：X 射线晶体学研究。
Mar Drugs. 2018 Jul 19;16(7):240. doi: 10.3390/md16070240.
8
Divergent Synthesis of Methylene Lactone- and Methylene Lactam-Based Spiro Compounds: Utility of Amido-Functionalized γ-Hydroxylactam as a Precursor for Cytotoxic ,- and ,-Spiro Compounds.基于亚甲基内酯和亚甲基内酰胺的螺环化合物的发散合成：酰胺基官能化γ-羟基内酰胺作为前体用于合成细胞毒性的、-和、-螺环化合物的应用。
J Org Chem. 2019 Oct 4;84(19):12532-12541. doi: 10.1021/acs.joc.9b02038. Epub 2019 Sep 17.
9
Synthesis of salinosporamide A and its analogs as 20S proteasome inhibitors and SAR summarization.沙利度胺类似物 A 的合成及其作为 20S 蛋白酶体抑制剂的应用及构效关系总结。
Curr Top Med Chem. 2011 Dec;11(23):2906-22. doi: 10.2174/156802611798281302.
10
Proteasome inhibitors: an expanding army attacking a unique target.蛋白酶体抑制剂：一支不断壮大的攻击独特靶点的队伍。
Chem Biol. 2012 Jan 27;19(1):99-115. doi: 10.1016/j.chembiol.2012.01.003.
引用本文的文献
1
Strain-release enables access to carbonyl conjugated allylic diborons and alkenyl boronates having multiple contiguous stereocenters in a one-pot process.应变释放能够通过一锅法获得具有多个连续立体中心的羰基共轭烯丙基二硼和烯基硼酸酯。
Chem Sci. 2024 Dec 2;16(3):1205-1215. doi: 10.1039/d4sc06514j. eCollection 2025 Jan 15.
2
Comparative genomics of the highly halophilic Haloferacaceae.高度嗜盐菌科的比较基因组学。
Sci Rep. 2024 Nov 6;14(1):27025. doi: 10.1038/s41598-024-78438-8.
3
Primed for Interactions: Investigating the Primed Substrate Channel of the Proteasome for Improved Molecular Engagement.做好相互作用的准备：研究蛋白酶体的预激活底物通道以改善分子结合。
Molecules. 2024 Jul 17;29(14):3356. doi: 10.3390/molecules29143356.
4
Chemical acylation of an acquired serine suppresses oncogenic signaling of K-Ras(G12S).化学酰化获得的丝氨酸可抑制 K-Ras(G12S)的致癌信号。
Nat Chem Biol. 2022 Nov;18(11):1177-1183. doi: 10.1038/s41589-022-01065-9. Epub 2022 Jul 21.
5
Flavan-3-ol Microbial Metabolites Modulate Proteolysis in Neuronal Cells Reducing Amyloid-beta (1-42) Levels.黄烷-3-醇微生物代谢物可调节神经元细胞中的蛋白水解，降低淀粉样β（1-42）水平。
Mol Nutr Food Res. 2021 Sep;65(18):e2100380. doi: 10.1002/mnfr.202100380. Epub 2021 Aug 7.
6
De Novo Structural Pattern Mining in Cellular Electron Cryotomograms.细胞电子断层扫描图中的从头结构模式挖掘。
Structure. 2019 Apr 2;27(4):679-691.e14. doi: 10.1016/j.str.2019.01.005. Epub 2019 Feb 7.
7
Design, synthesis, and evaluation of cystargolide-based β-lactones as potent proteasome inhibitors.基于胱硫醚酶的β-内酰胺的设计、合成与评价作为有效的蛋白酶体抑制剂。
Eur J Med Chem. 2018 Sep 5;157:962-977. doi: 10.1016/j.ejmech.2018.08.052. Epub 2018 Aug 20.
8
(-)-Homosalinosporamide A and Its Mode of Proteasome Inhibition: An X-ray Crystallographic Study.(-)-Homosalinosporamide A 及其蛋白酶体抑制模式：X 射线晶体学研究。
Mar Drugs. 2018 Jul 19;16(7):240. doi: 10.3390/md16070240.
9
Fundamental reaction pathway and free energy profile of proteasome inhibition by syringolin A (SylA).丁香皮素A（SylA）抑制蛋白酶体的基本反应途径和自由能分布图。
Org Biomol Chem. 2015 Jun 28;13(24):6857-65. doi: 10.1039/c5ob00737b.
10
Fundamental reaction pathway for peptide metabolism by proteasome: insights from first-principles quantum mechanical/molecular mechanical free energy calculations.蛋白酶体介导的肽代谢的基本反应途径：从头算量子力学/分子力学自由能计算的见解。
J Phys Chem B. 2013 Oct 31;117(43):13418-34. doi: 10.1021/jp405337v. Epub 2013 Oct 10.
本文引用的文献
1
Chemical genetics: exploring the role of the proteasome in cell biology using natural products and other small molecule proteasome inhibitors.化学遗传学：利用天然产物和其他小分子蛋白酶体抑制剂探索蛋白酶体在细胞生物学中的作用。
J Med Chem. 2008 May 8;51(9):2600-5. doi: 10.1021/jm070421s. Epub 2008 Apr 5.
2
20S proteasome and its inhibitors: crystallographic knowledge for drug development.20S蛋白酶体及其抑制剂：药物研发的晶体学知识
Chem Rev. 2007 Mar;107(3):687-717. doi: 10.1021/cr0502504. Epub 2007 Feb 23.
3
Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy.蛋白酶体的功能：从蛋白质降解、免疫监视到癌症治疗
Biochem Soc Trans. 2007 Feb;35(Pt 1):12-7. doi: 10.1042/BST0350012.
4
Alpha,beta-unsaturated beta-silyl imide substrates for catalytic, enantioselective conjugate additions: a total synthesis of (+)-lactacystin and the discovery of a new proteasome inhibitor.用于催化对映选择性共轭加成的α，β-不饱和β-硅基酰亚胺底物：（+）-乳胞素的全合成及一种新型蛋白酶体抑制剂的发现
J Am Chem Soc. 2006 May 31;128(21):6810-2. doi: 10.1021/ja061970a.
5
Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding.与20S蛋白酶体结合的盐霉素A（NPI-0052）和B（NPI-0047）的晶体结构揭示了β-内酯环开环的重要影响以及不可逆结合的机制。
J Am Chem Soc. 2006 Apr 19;128(15):5136-41. doi: 10.1021/ja058320b.
6
Inhibitor-binding mode of homobelactosin C to proteasomes: new insights into class I MHC ligand generation.同型β-内酰胺菌素C与蛋白酶体的抑制剂结合模式：对I类主要组织相容性复合体配体生成的新见解
Proc Natl Acad Sci U S A. 2006 Mar 21;103(12):4576-9. doi: 10.1073/pnas.0600647103. Epub 2006 Mar 13.
7
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.基于硼酸的蛋白酶体抑制剂硼替佐米与酵母20S蛋白酶体复合物的晶体结构。
Structure. 2006 Mar;14(3):451-6. doi: 10.1016/j.str.2005.11.019.
8
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate.蛋白酶体不同蛋白水解位点的重要性以及抑制剂的功效会因蛋白质底物而异。
J Biol Chem. 2006 Mar 31;281(13):8582-90. doi: 10.1074/jbc.M509043200. Epub 2006 Feb 2.
9
Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates.使用荧光肽底物监测26S蛋白酶体的活性和抑制作用。
Methods Enzymol. 2005;398:364-78. doi: 10.1016/S0076-6879(05)98030-0.
10
Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach.真核生物20S蛋白酶体核心颗粒抑制剂：一种结构学方法。
Biochim Biophys Acta. 2004 Nov 29;1695(1-3):33-44. doi: 10.1016/j.bbamcr.2004.09.025.
Zotero 插件